

EINLADUNG

House of Pharma & Healthcare Perspektivengespräch

Montag, 20. Juni 2016, 18:00 Uhr

Alte Aula, Alte Universität, Philipps-Universität Marburg



Francois P. Roman, MD, PhD

Clinical and Epidemiological Project Lead, Belgium

François Roman is a medical doctor working as Director, Clinical and Epidemiological Project Lead (CEPL) at GlaxoSmithKline Vaccines, where he leads the clinical development of Ebola, HIV, Tuberculosis and Malaria vaccines. He completed an MD (1996) and a PhD degree (2006) from the Catholic University of Louvain, Belgium, and was trained as an infectious disease specialist.

Before joining GlaxoSmithKline Vaccines, he worked as research fellow, then as head of the clinical virology unit at the Retrovirology Laboratory of Luxembourg (1999-2007). During that period, he focused his research on HIV-1 entry and entry inhibition and on the molecular epidemiology of chronic viral infections. He joined GlaxoSmithKline Vaccines in 2007 where he served as Senior Manager then Director in the clinical development of vaccine programs including Flu Seasonal and Pandemic, HIV, COPD, CMV and Ebola, Malaria and Tuberculosis vaccines.



Prof. Dr. Stephan Becker

Institut für Virologie, Philipps-Universität Marburg

Stephan Becker heads the Institut für Virologie and is professor at Philipps-Universität Marburg. He studied pharmaceutical science in Marburg. He completed his PhD on energy metabolism of tumor cells in 1989 and joined the Institut für Virologie in Marburg as postdoc. There he started working with Marburg and Ebola virus. He became head of the high security lab in Marburg (1995) and moved to the Robert-Koch-Institut, Berlin, in 2005.

In 2007, he was appointed director and chair of the Institute für Virologie at Marburg University. His main research focus is pathogenesis of viruses that cross the species border and cause severe disease in humans such as Ebola and Marburg virus. In addition, Stephan Becker is interested in host - pathogen interactions enabling viral replication and intracellular transport. He is the coordinator of the section Emerging Infections of the German Center of Infection Research (DZIF). This consortium develops emergency vaccines and broad spectrum antivirals against highly pathogenic zoonotic viruses and was involved in testing one of the Ebola virus vaccines in clinical trials.

Vaccines against Ebola and other emerging viruses

Zoonotic viruses that cross the species barrier can induce severe disease in humans and are of great concern to public health. Recent evidence of the dramatic consequences such events might have is the Ebola virus outbreak in West Africa which caused more than 11 thousand deaths and threatened to destabilize a whole region

Only unprecedented international efforts were able to finally contain this outbreak. This outbreak showed the crucial need to produce antivirals and specific preventive vaccines also for the rare highly pathogenic viruses of no commercial interest. Those pathogens might have

a strong impact on the health care systems of resource limited countries and are also difficult to manage in developed countries. It is therefore necessary to develop strategies that aim at improving our preparedness to fight those neglected tropical diseases. The House of Pharma lectures will address the question of how public-private-partnership can support the development and production of emergency vaccines against Ebola and other emerging viruses.

House of Pharma & Healthcare

Das House of Pharma & Healthcare verfolgt das Ziel der Weiterentwicklung des Pharma-Kompetenzclusters in Hessen. Es fördert die Entwicklung, Integration und Anwendung von Wissen in der biomedizinischen Forschung und koordiniert die gemeinsamen Bemühungen von Wirtschaft und Wissenschaft zur Steigerung der Leistungsfähigkeit der Arzneimittelforschung und Entwicklung. Dafür bindet das House of Pharma & Healthcare Interessenvertreter aller Stufen der pharmazeutischen Wertschöpfungskette mit dem Ziel ein, die internationale Sichtbarkeit Deutschlands in der translationalen biomedizinischen Forschung zu erhöhen und die Innovationslücke in der Arzneimittelentwicklung zu schließen.

Wissens- und Wirtschaftsstandort Hessen

Durch die nachhaltige Sicherung und den Ausbau des Wissens- und Wirtschaftsstandortes Hessen sollen zudem die Bedingungen für Existenzgründungen und die Schaffung neuer Arbeitsplätze gefördert werden.

20. JUNI 2016

Programm

18:00 UHR

BEGRÜSSUNG

[Prof. Dr. Jochen Maas](#)

Präsidium des House of Pharma & Healthcare e.V.

—

VORTRAG

Ebola: Vom der Epidemie zum Impfstoff

[Francois P. Roman](#)

Director, Clinical and Epidemiological Project Lead (CEPL),
GlaxoSmithKline Vaccines

[Prof. Dr. Stephan Becker](#)

Institut für Virologie, Philipps-Universität Marburg

—

DISKUSSION

ANMELDUNG

Zur Veranstaltung

WIR BITTEN UM ANMELDUNG UNTER:

www.houseofpharma.de/ebola

E-Mail: Anmeldung@houseofpharma.de

Tel.: 069-6301-84900

Fax: 069-6301-7636

[ZUR ONLINE-ANMELDUNG »](#)



VERANSTALTUNGSORT

Alte Universität – Alte Aula

Lahntor 3, 35037 Marburg

Der Eingang zur Alten Aula innerhalb der Alten Universität befindet sich in der Reitgasse unterhalb der Universitätskirche

Zufahrt:

Bitte nutzen Sie das Parkhaus Pilgrimstein, mit dem Aufzug im Parkhaus bzw. dem Oberstadtaufzug gelangen Sie über die Reitgasse zur Alten Aula der Philipps-Universität.



„Investitionen in Ihre Zukunft“



Investitionen des House of Pharma & Healthcare wurden von der Europäischen Union aus dem Europäischen Fonds für regionale Entwicklung und vom Land Hessen kofinanziert.